Related Experiment Videos
Alternative and aberrant splicing of MDM2 mRNA in human cancer
Frank Bartel1, Helge Taubert, Linda C Harris
1Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Abstract:
MDM2 has been characterized as a protein that binds to and facilitates degradation of the tumor suppressor p53. Interestingly, more than 40 different splice variants of MDM2 transcripts have been identified both in tumors and normal tissues, and the majority of these variants do not contain sequence encoding the p53 binding site. This review describes the different splice forms, the tissues in which they have been identified, and their association with tumor progression and prognosis. In addition, we discuss the potential functions of these variants and how they interact with full-length MDM2 protein.
Insights
Over 40 MDM2 splice variants exist, mostly lacking the p53 binding site. This review explores their roles in tumor progression and potential functions.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MDM2 protein targets the tumor suppressor p53 for degradation.
- Over 40 MDM2 splice variants have been identified in various tissues.
- Most MDM2 variants lack the p53-binding domain found in the full-length protein.
Purpose of the Study:
- To review identified MDM2 splice variants.
- To discuss their tissue distribution and association with cancer.
- To explore potential functions and interactions of MDM2 variants.
Main Methods:
- Literature review of MDM2 splice variants.
- Analysis of variant identification in different tissues.
- Examination of correlations between variants and tumor progression/prognosis.
Main Results:
- Identification of numerous MDM2 splice variants.
- Localization of variants in both normal and tumor tissues.
- Association of certain variants with tumor progression and patient prognosis.
Conclusions:
- MDM2 splice variants represent a significant area of cancer research.
- Understanding these variants is crucial for comprehending MDM2's role in cancer.
- Further research into MDM2 variant functions may reveal new therapeutic targets.